Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## **144: Filer Information**

Filer CIK0001381994Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationIs the second second

Name Phone E-Mail Address

## **144: Issuer Information**

Name of Issuer	ALNYLAM PHARMACEUTICALS, INC.
SEC File Number	001-36407
Address of Issuer	675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MASSACHUSETTS 02142
Phone	(617) 551-8200
Name of Person for Whose Account the Securities are To Be Sold	Ausiello Dennis A
See the definition of "person" in paragraph (a) of Rule 144. Informatio	on is to be given not only as to the person for whose

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Director

#### **144: Securities Information**

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 1000 Harbor 3rd Floor Weehawken NJ 07016	20250	5399865.00	128380513	08/06/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

# **144: Securities To Be Sold**

Title of the Date you

Nature of

Name of

Is Date

Amount of

Nature of

Date of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	Donor Acquired		Payment	Payment *
Common	08/06/2024 <mark>E</mark>	Exercise of Stock Option	Issuer		20250	08/06/2024 Ca	sh

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Nothing to Report

## 144: Remarks and Signature

ATTENTION:	
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/03/2024
Date of Notice	08/06/2024
Remarks	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Dennis Ausiello

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)